Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study

Table 3 Multivariate analysis of between peripheral hematology and treatment effect in patients with advanced tumor treated by ICI

SD + PR/PR	B	S.E	Wald	df	Sig	Exp(B)	95% CI for Exp(B)
SD + PR/PR	B	S.E	Wald	df	Sig	Exp(B)	Lower	Upper
SD + PR
NER	− 0.001	0.001	0.892	1	0.345	0.999	0.997	1.001
PNI	0.051	0.041	1.581	1	0.209	1.053	0.972	1.141
Hb	0.009	0.009	0.934	1	0.334	1.009	0.991	1.027
RBC	0.016	0.064	0.065	1	0.799	1.016	0.897	1.152
PR
RBC	− 0.024	0.081	0.091	1	0.763	0.976	0.833	1.144
Hb	0.000	0.008	0.002	1	0.965	1.000	0.985	1.016

CI Confidence interval, SD Stable disease, PR Partial response, NER Neutrophil-eosinophil ratio, PNR Prognostic nutritional index, Hb Hemoglobin, RBC Red blood cell, PD-L1 Programmed cell death-ligand 1, TMB-H Tumor mutational burden-high, MSI-H Microsatellite instability-high, dMMR Different mismatch repair
P < 0.05 is statistically significant; PD-L1 ≥ 1%

ISSN: 1477-7819